10 results about "Prognosis biomarker" patented technology

The application discloses a liver cancer prognosis marker and application thereof, and the liver cancer prognosis marker comprises TXNRD1, HAO1, C1S, OPTN and SNX6. The application provides a group of liver cancer prognosis markers, and a liver cancer patient prognosis prediction model is constructed based on the liver cancer prognosis markers. The liver cancer prognosis markers are obtained through comprehensive gene expression levels, single cell analysis and spatial transcriptome analysis, and the diversity of the data set and the large sample quantity improve the reliability and universality of the liver cancer prognosis markers and the liver cancer patient prognosis prediction model.

This invention belongs to the field of biomedical technology, specifically relating to the application of a pharmaceutical composition consisting of denosumab combined with an immune checkpoint inhibitor in the preparation of a drug for treating KRAS-mutant advanced non-small cell lung cancer (NSCLC). Addressing the problems of high toxicity, limited efficacy, and lack of effective prognostic biomarkers in existing maintenance therapy for KRAS-mutant advanced NSCLC, this invention experimentally demonstrates that maintenance therapy with denosumab combined with a PD-1 / PD-L1 inhibitor can significantly prolong overall survival in patients with KRAS-mutant advanced NSCLC who have not progressed after 4-6 cycles of first-line immunochemotherapy, with a lower incidence of treatment-related adverse events and better safety, especially in patients with KRAS-G12C mutations. Furthermore, this invention discovers that plasma CCER2 can serve as a prognostic biomarker. This invention provides a new, low-toxicity, high-benefit strategy for KRAS-mutant advanced NSCLC and also provides a liquid biopsy biomarker that can be used for patient stratification, possessing significant clinical application value.

The application discloses application of TGM2 as a cervical cancer diagnosis, prognosis biomarker and therapeutic target. The application provides a new cervical cancer diagnosis and prognosis marker TGM2, which can clearly characterize the occurrence and development of cervical cancer; the marker presents specific high expression phenomenon in comparison with normal tissue in human clinical cervical cancer tissue; and the marker also presents high expression in human cervical cancer cell lines. Knocking down TGM2 can inhibit the proliferation and migration ability of cervical cancer cells; TGM2, as an enzyme, has high application potential as a diagnosis and treatment target. The application provides a new marker and target for the diagnosis, prognosis and treatment of cervical cancer, and can provide a new strategy and direction for the treatment of cervical cancer.

The application belongs to the technical field of medical treatment and discloses a cancer prognosis marker combination and application thereof, which comprises the following markers: CD68, PD-L1, PAN-CK, HLA-DR, CD45, CD11c and Collagen I. The cancer prognosis evaluation model trained by using the 7-marker combination exhibits superior prognosis accuracy compared to a model relying on high-dimensional multi-omics data. The application proposes a multiple immunohistochemistry (mIHC) cancer prognosis evaluation detection product based on the above-mentioned cancer prognosis marker combination. Satisfactory prognosis results are achieved by using only two five-marker combinations. The method exhibits high accuracy in predicting the survival of gastric cancer patients, so that it becomes a low-cost, high-benefit and scalable solution for other cancers.

The application relates to the technical field of melanoma prognosis, and provides a construction method and a verification method of a melanoma prognosis model based on a lactation gene methylation feature. The DNA methylation data of a cancer genome atlas database is taken as a training set, and the DNA methylation data of a gene expression comprehensive database is taken as a verification set, so that the lactation-related gene methylation feature prognosis marker model of melanoma constructed has good external applicability. A methylation site pair matrix is constructed through the relative methylation order relationship of the methylation sites, so that the batch effect between different data sets is effectively avoided, and excellent robustness and clinical applicability are achieved. The methylation sites corresponding to the lactation-related gene set are taken as anchor points to perform hierarchical clustering and differential methylation site screening, functional sites related to prognosis are screened out, the reliability of the constructed prognosis marker model is improved, and the accuracy of prognosis prediction is improved.

The application discloses application of long-chain non-coding RNA MYLK-AS1 as a biomarker in preparation of a kit for diagnosis or prognosis of acute myeloid leukemia. The application aims to provide a marker for diagnosis and / or prognosis of acute myeloid leukemia and a target point for treatment. The application discloses application of LncRNA-MYLK-AS1 as a biomarker in preparation of a kit for diagnosis and / or prognosis of acute myeloid leukemia, and the gene of the LncRNA-MYLK-AS1 is shown as SEQ ID NO. 1. The LncRNA-MYLK-AS1 provided by the application has the advantages of simple operation, accurate detection, and suitability for clinical screening, and provides more information for diagnosis and prognosis of AML, and lays a foundation for targeted treatment of AML.

This invention discloses a biomarker for early diagnosis, assessment of disease progression, and prognostic evaluation in patients undergoing intravenous thrombolysis for acute ischemic stroke: Syndecan-1 in peripheral blood. This invention provides the application of a substance for detecting Syndecan-1 in peripheral blood in the preparation of products for early diagnosis of prognosis in patients undergoing intravenous thrombolysis for acute ischemic stroke; or in the preparation of products for assessing disease progression in patients undergoing intravenous thrombolysis for acute ischemic stroke; or in the preparation of products for assessing the prognosis of patients undergoing intravenous thrombolysis for acute ischemic stroke. Research results indicate that plasma Syndecan-1 levels represent a novel and independent prognostic biomarker that can improve the current risk stratification of patients undergoing intravenous thrombolysis for acute ischemic stroke. Blood tests are easily accepted by patients and can serve as an effective means for early diagnosis, assessment of disease progression, and prognostic evaluation in patients undergoing intravenous thrombolysis for acute ischemic stroke.

The application provides a nasopharyngeal carcinoma patient prognosis biomarker and application thereof, and the biomarker is CD8+ZNF683+. Compared with a primary treatment sample, the proportion of CD8+ZNF683+ T cells in a recurrent nasopharyngeal carcinoma sample is significantly increased. Compared with a nasopharyngeal carcinoma patient with a low proportion of CD8+ZNF683+ cells, a recurrent nasopharyngeal carcinoma patient with a high proportion of CD8+ZNF683+ cells has a poorer OS and LRRFS, and has a poorer survival outcome. Therefore, the CD8+ZNF683+ cells can be used as a specific biomarker for the prognosis of a nasopharyngeal carcinoma patient, and the recurrence and survival outcome of the nasopharyngeal carcinoma patient are evaluated.